Company intelligence / Profile preview

CovalX

Zürich, Zurich, Switzerlandcovalx.com ↗

Ownership: Private
Development stage: Other

Overview

CovalX provides advanced analytical solutions—especially epitope mapping and protein interaction analysis using high-mass MALDI mass spectrometry—to support the development and characterization of therapeutic proteins. The company serves major pharmaceutical companies and academic labs globally with both products and contract research services. No clinical results as it does not develop drugs directly.

Therapeutic areas: Other
Modalities: Monoclonal antibody (mAb)Protein (Therapeutic protein characterization)Biologic (General focus on biologics analytics)
Industry: Drug Discovery Services

Partnerships

Major pharmaceutical companies as clients/users of their technology/services

Beyond the preview

Go deeper on CovalX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CovalX.

Explore the full profile